Entera Bio Ltd (ENTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $541.57M
Last updated: Nov 17, 2026 at 11:04 AM ET
Entera Bio Ltd (ENTX) Stock Forecast
Analysts expect Entera Bio (ENTX) to earn -$0.42 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.44.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.42
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.44
- EPS consensus
- Next report
- Mar 25, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.42 | -$0.62 to -$0.31 | 4 |
| Dec 31, 2027 | -$0.44 | -$0.57 to -$0.32 | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.13 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.21 to -$0.05 | 7 |
| Mar 31, 2027 | -$0.13 | -$0.13 to -$0.12 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.34.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.42 | -$0.40 | -$0.40 | -$0.34 | -$0.34 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.44 | -$0.42 | -$0.42 | -$0.57 | -$0.57 | N/A |
| Quarter ending Mar 31, 2027 | -$0.13 | -$0.12 | -$0.12 | -$0.13 | -$0.13 | N/A |
Frequently Asked Questions About ENTX
What is the ENTX stock forecast?
Consensus analyst estimates put Entera Bio's EPS at -$0.42 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Buy.
How do analysts rate ENTX stock?
Of 5 analysts covering Entera Bio, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ENTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.42, with estimates from -$0.62 to -$0.31 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.44, with estimates from -$0.57 to -$0.32 from 5 analysts.
How many analysts cover ENTX?
5 analysts rate Entera Bio stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ENTX pages: Overview, Earnings, Forecast, Financials, Competitors